Gerrish Philip J, García-Lerma J Gerardo
Department of Applied Mathematics, Instituto Mexicano del Petróleo, Colonia San Bartolo Atepehuacan, Distrito Federal, México.
Lancet Infect Dis. 2003 Jan;3(1):28-32. doi: 10.1016/s1473-3099(03)00485-7.
Despite rapid progress in drug development, microbial infections in general are becoming increasingly difficult to treat as a result of the emergence of drug-resistant strains. In some cases, such as HIV-1, the early goal of eradicating infections with antimicrobial drugs is, for now, being replaced with the more pragmatic goal of controlling infections over long periods of time through a succession of transiently effective treatments. Because treatment efficacy is often incomplete, studying the degree of treatment efficacy has great relevance to clinical disease management. We derived a model describing the association between the mutation rate of the pathogen and the degree of treatment efficacy. We found that drug treatment is most effective when the mutation rate of the pathogen is either very low or, perhaps counterintuitively, very high. We discuss this finding in the light of a promising new treatment strategy for RNA viruses that combines antiviral compounds with a mutagen.
尽管在药物研发方面取得了快速进展,但由于耐药菌株的出现,一般来说微生物感染正变得越来越难以治疗。在某些情况下,如HIV-1,目前用抗菌药物根除感染的早期目标正被更务实的目标所取代,即通过一系列暂时有效的治疗来长期控制感染。由于治疗效果往往不完全,研究治疗效果的程度与临床疾病管理密切相关。我们推导了一个描述病原体突变率与治疗效果程度之间关联的模型。我们发现,当病原体的突变率非常低或者(也许与直觉相反)非常高时,药物治疗最有效。我们根据一种将抗病毒化合物与诱变剂相结合的、有前景的RNA病毒新治疗策略来讨论这一发现。